Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Cash & Equivalents (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Cash & Equivalents for 6 consecutive years, with $105.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 23.22% to $105.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $105.0 million, a 23.22% increase, with the full-year FY2025 number at $105.0 million, up 23.22% from a year prior.
  • Cash & Equivalents was $105.0 million for Q4 2025 at GeneDx Holdings, up from $96.0 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $461.3 million in Q3 2021 to a low of $26.5 million in Q2 2021.
  • A 5-year average of $153.3 million and a median of $99.7 million in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 40363.55% in 2021, then tumbled 69.06% in 2022.
  • GeneDx Holdings' Cash & Equivalents stood at $400.6 million in 2021, then crashed by 69.06% to $123.9 million in 2022, then decreased by 19.57% to $99.7 million in 2023, then decreased by 14.52% to $85.2 million in 2024, then rose by 23.22% to $105.0 million in 2025.
  • Per Business Quant, the three most recent readings for WGS's Cash & Equivalents are $105.0 million (Q4 2025), $96.0 million (Q3 2025), and $74.1 million (Q2 2025).